J&J moves forward with next-gen insulin delivery

Johnson & Johnson's ($JNJ) Animas is progressing with its investigational artificial pancreas--an insulin-delivery device that can detect blood glucose in the body and automatically normalize levels. The company is plotting a second feasibility study of the platform on the heels of positive results from a trial of 13 adult patients with Type 1 diabetes, its CMO told FierceMedicalDevices. But J&J isn't the only game in town. With rates of diabetes on the rise in the U.S. and abroad, drug delivery companies and devicemakers are working to develop next-generation insulin-delivery technologies, with big guns like Medtronic ($MDT) creating a combination glucose monitor/insulin pump and smaller companies like Transdermal Specialties developing a needle-free insulin patch. Report